Healthcare Industry News: HSMN NewsFeed

Diagnostics HIV/AIDS FDA

 News Release - November 6, 2018

FDA Approves Ortho Clinical Diagnostics VITROS(R) Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator for use on the VITROS(R) 5600 Integrated System

Expanded use on the VITROS® 5600 Integrated System will help Labs Maximize Workflow Efficiencies

RARITAN, N.J., Nov. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Ortho Clinical Diagnostics, a global leader of in vitro diagnostics, announced that the VITROS® Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator (VITROS® HIV Combo test) received approval from the U.S. Food and Drug Administration for use on Ortho's VITROS® 5600 Integrated System1.

VITROS® HIV Combo, a fourth-generation test, detects both HIV-1 and HIV-2 antibodies (Ab) and the p24 antigen (Ag), enabling detection of acute HIV-1 infection earlier than third-generation tests2.

According to estimates by the World Health Organization (WHO), 37 million people worldwide are living with HIV today3. Starting antiretroviral treatment as soon as possible after diagnosis can help avert millions of AIDS-related deaths and new infections. According to the U.S. Centers for Disease Control and Prevention, identifying patients in the early stages of infection is crucial2.

"Ortho is committed to expanding its assay menu to meet current guidelines and testing needs," said Jennifer Paine, Ortho's EVP and Chief Product Portfolio and QRC Officer. "With the availability of the VITROS® HIV Combo test on the VITROS® 5600 System, laboratories can improve workflow efficiencies while helping to provide earlier detection of HIV infection."

The clinical and technical performance of the VITROS HIV Combo test on VITROS® Systems was evaluated at three external testing laboratories in the US and at Ortho's research and development laboratories. This assessment confirmed that the test provides competitive sensitivity and specificity when compared to a leading commercially available fourth-generation test4.

In the comparison studies4, assay sensitivity was evaluated on seroconversion panels. The VITROS® HIV Combo test showed earlier detection of acute HIV infection in six of 32 seroconversion panels (agreement for 25 of 32 panels) when compared to a leading commercially available fourth-generation Ag/Ab test, indicating that the assay performance is very competitive in shortening the diagnostic window (the time between HIV infection and detection) - a valuable attribute in HIV testing.

The test's excellent p24 sensitivity with uncompromised specificity4 is enhanced by a combination of proprietary technologies and benefits only available on VITROS® Systems. These provide laboratories the accuracy needed to have the utmost trust in their results.

About The VITROS® Systems

The VITROS® Chemistry, Immunodiagnostic and Integrated Systems from Ortho Clinical Diagnostics is a portfolio of products and patented enabling technologies that help clinical laboratories diagnose, monitor and treat disease. VITROS® Systems are engineered to help clinical laboratories with organizational, operational and economic challenges.

About Ortho Clinical Diagnostics

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the global clinical laboratory and immunohematology communities. Across hospitals, hospital networks, blood banks, and labs in more than 125 countries and territories, Ortho's high-quality products and services enable health care professionals to make better-informed treatment decisions. Ortho brings sophisticated testing technologies, automation, and information management and interpretation tools to clinical laboratories around the world to help them run more efficiently and effectively and improve patient care. For the immunohematology community, Ortho's blood typing products help ensure every patient receives blood that is safe, the right type and the right unit. Ortho's purpose is to improve and save lives with diagnostics, and it does that by reimagining what's possible. This is what has defined Ortho for more than 75 years, and it's what drives Ortho forward. For more information, visit www.orthoclinicaldiagnostics.com.

VITROS® is a trademark of Ortho Clinical Diagnostics.

© Ortho Clinical Diagnostics 2018

1 The VITROS® HIV Combo test is not currently approved or available in the United States for use on VITROS ECi/ECiQ Immunodiagnostic Systems

2 http://www.cdc.gov/std/treatment/2010/hiv.htm

3 http://www.who.int/hiv/en/

4 VITROS® HIV Combo Instructions for Use


Source: Ortho Clinical Diagnostics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.
RepFinder 2 - available on the Apple App Store for iPhone and iPad.